Roche wins EU backing for better Esbriet label; Pfizer kicks Remoxy back to Pain Therapeutics;

@FiercePharma: EMA favors AstraZeneca's ovarian cancer drug Lynparza that FDA committee dissed. ICYMI Friday | Follow @FiercePharma

@EricPFierce: #Novorossiya gets subpoenaed for information about a manufacturing plant in #DenmarkHill. More | Follow @EricPFierce

@CarlyHFierce: Fed up with Allergan obstinance, Valeant CEO says he'd hike bid past $200 a share. News | Follow @CarlyHFierce

> European drug regulators recommended a labeling update for Roche's ($RHHBY) new idiopathic pulmonary fibrosis drug Esbriet, to emphasize the drug's ability to reduce the risk of death and reinforce its safety profile. Release

> Pfizer ($PFE) kicked the painkiller Remoxy back to Pain Therapeutics after winning approval last week for new tamper-resistant labeling on its pain pill Embeda. Release

> Eli Lilly ($LLY) says it will sell some of Novartis' ($NVS) animal health products to Virbac, after the Indianapolis-based drugmaker closes it buyout of the Novartis unit. Report

> Brazil's pharmaceuticals and consumer health products company Hypermarcas delivered a 48% jump in third-quarter profits thanks to a currency hedge; sales grew by 7%. Report

> Some regulatory lawyers are taking issue with changes the FDA made to new guidance on facility inspections. Report

Medical Device News

@FierceMedDev: ICYMI Friday: New microscope offers 3D cellular images that are fast, detailed and low toxicity. Article | Follow @FierceMedDev

@VarunSaxena2: Edwards profit up 23%, but increased TAVR competition looming. Story | Follow @VarunSaxena2

@EmilyWFierce: ICYMI Friday: $JNJ scores victory in first metal-on-metal hip implant case to go to trial. Article | Follow @EmilyWFierce

> St. Jude Medical snags FDA approval for next-generation ablation catheter. More

> Attorney: FDA final guidance on product recalls not helpful. Story

> Boston Children's Hospital debuts 'Baby MEG' brain imaging system. Article

Biotech News

@FierceBiotech: Sarepta plunges as CEO moves goal line on Duchenne MD drug downfield. Report | Follow @FierceBiotech

@JohnCFierce: Les Echos and Bloomberg both say Viehbacher future in doubt at Sanofi ... among the chief irritants: Viehbacher's move to Boston. | Follow @JohnCFierce

@DamianFierce: Viehbacher's letter to the $SNY board is a wincing read. "Ask Len Schleifer about me!" | Follow @DamianFierce

@EmilyMFierce: Managers of discredited STAP stem cell study refund salary. More from Science | Follow @EmilyMFierce

> Akebia craters as adverse events cloud positive PhIIb anemia data. Article

> INC Research spells out details on $150M IPO. Item

> Pfizer finally abandons all hope in Remoxy, and Durect/Pain Therapeutics feel the sting. Report

CRO News

> SRI's CRO cuts the ribbon on a new early-phase outpost. Item

> MPI buys out a CRO neighbor to bolster early-stage R&D. More

> CROs line up to advise Big Pharma's R&D think tank. Story

> WuXi teams up with Foundation Medicine to bring cancer profiling to China. Article

> Icon posts another revenue jump and dials up its expectations. Report

Biotech IT News

> Billionaire doc teams with Oxford Uni to build 'NASA of biomedicine.' More

> NIH-funded registry of patient-entered genetic data goes live. News

> 23andMe steps up R&D with new hire, poster push. Report

> Human Longevity backer creates $100M fund for 'crazy' ideas. Story

> Microsoft makes cloud-computing available to Ebola researchers. Article

Animal Health News

> USDA awards $4.5M to vets working in underserved areas. Article

> VCA beats Q3 estimates on same-store hospital sales growth. Report

> Are flea-fighting pills gaining ground on OTC topicals? Item

> K-State, Lawrence Livermore team on Dx tools to detect infectious diseases. Story

> Report: Pet owners jump on the probiotics bandwagon. More

And Finally... Ebola-related quarantines are triggering controversy. Report (sub. req.) | Report

Suggested Articles

AbbVie has seen blossoming market share for immunology launches Rinvoq and Skyrizi—and it's eyeing Allergan's neurology biz for a boost, too.

While Novo's Rybelsus launch has slowed due to the pandemic, another version of the med, Ozempic posted strong sales.

AZ sold Atacand and Atacand Plus rights in about 70 countries to Cheplapharm.